Literature DB >> 3199317

Effect of a protein binding change on unbound and total plasma concentrations for drugs of intermediate hepatic extraction.

R H Smallwood1, G W Mihaly, R A Smallwood, D J Morgan.   

Abstract

For substances eliminated from blood by the liver, the effect of a change in unbound fraction of drug (fu(b)) on steady state total (Cb) and unbound (Cu(b)) blood concentrations has hitherto only been considered for the two limiting cases, i.e., at the upper and lower extremes of hepatic intrinsic clearance (CL(int)). For a substance of very low CL(int), if fu(b) changes, Cb will change and Cub will remain constant, whereas if CL(int) is very high, Cub will change and Cb will remain constant. The present study defines the effects of a change in fu(b) on Cb and Cub over the whole CL(int) range. Computer simulations were undertaken which predicted that, for a given change in fu(b), absolute and relative changes in Cb would decrease nonlinearly with increasing CL(int), while the relative change in Cub would increase with CL(int). The absolute change in Cub would be independent of CL(int). Significant changes in Cb and Cub would be observed at intermediate values of CL(int) not just at the high and low extremes. These theoretical predictions were investigated experimentally in the isolated perfused rat liver by examining the effects of a change in fu(b) of sodium taurocholate a substance with intermediate CL(int) (such that at fu(b) = 0.27, hepatic extraction ratio = 0.71) induced by concurrent administration of sodium oleate. Sodium 24-14 C-taurocholate (specific activity 52 microCi/mmol) was infused into the reservoir in a recycling system at 30 mumol/hr for 105 min (n = 6). At 45 min a bolus dose of sodium oleate (50 mmol) was administered to the reservoir, followed by a constant infusion of 143 mmol/hr for 1 hr. Following the administration of oleate, taurocholate fu(b) fell promptly by 55% (0.27-0.12). There was a relative increase of taurocholate Cb of 22.7% and a relative decrease in Cub of 45.4%, in accordance with the simulations (p less than 0.05). We conclude that important changes in unbound steady-state concentration, the pharmacologically active moiety, can occur upon changes in unbound fraction with compounds of intermediate hepatic intrinsic clearance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199317     DOI: 10.1007/bf01062383

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  Effect of salicylic acid on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia.

Authors:  S Oie; G Levy
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

2.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

3.  Canalicular bile formation in the isolated perfused rat liver.

Authors:  J L Boyer
Journal:  Am J Physiol       Date:  1971-10

4.  Colorimetric determination of free fatty acids.

Authors:  R R Lauwerys
Journal:  Anal Biochem       Date:  1969-11       Impact factor: 3.365

5.  Binding of sodium taurocholate by bovine serum albumin.

Authors:  H O Green; J Moritz; L Lack
Journal:  Biochim Biophys Acta       Date:  1971-05-04

6.  Effect of plasma protein binding on elimination of taurocholate by isolated perfused rat liver: comparison of venous equilibrium, undistributed and distributed sinusoidal, and dispersion models.

Authors:  R H Smallwood; D J Morgan; G W Mihaly; D B Jones; R A Smallwood
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

Review 7.  Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites.

Authors:  P F D'Arcy; J C McElnay
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

8.  Importance of protein binding for the interpretation of serum or plasma drug concentrations.

Authors:  D J Greenblatt; E M Sellers; J Koch-Weser
Journal:  J Clin Pharmacol       Date:  1982 May-Jun       Impact factor: 3.126

Review 9.  Kinetics of drug--drug interactions.

Authors:  L Aarons
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

10.  Effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia.

Authors:  S Oie; G Levy
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

View more
  6 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

4.  The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.

Authors:  B T Veering; A G Burm; J H Souverijn; J M Serree; J Spierdijk
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

5.  An understanding of flow- and diffusion-limited vs. carrier-mediated hepatic transport: a simulation study.

Authors:  W P Geng; K Poon; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

6.  Nonlinear protein binding and enzyme heterogeneity: effects on hepatic drug removal.

Authors:  X Xu; P Selick; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1993-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.